Company intelligence / Profile preview

NexGen Bio

Geumcheon-gu, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

NexGen Bio has multiple commercialized cosmeceutical products (including EGF-based lotions, creams, gels, and essence) and is a recognized innovator in recombinant protein engineering. It has developed rapid diagnostic kits (e.g., pregnancy tests), recombinant antigen proteins for infectious disease diagnostics, and received awards for protein production innovations, such as artificial spider venom protein manufacture.[1][2]

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Recombinant proteinDiagnostic deviceCosmeceutical
Industry: Biotech

Beyond the preview

Go deeper on NexGen Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NexGen Bio.

Explore the full profile